KIR2DL2

KIR2DL2 Informations sur la molécule

Nom anglais	Killer cell immunoglobulin-like receptor 2DL2	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1	Alias de la cible	CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Killer cell immunoglobulin-like receptor 2DL2
Alias de la cible	CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Phase 2 Clinical

KIR2DL2 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
Fc Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
KI2-H5255	Human	HEK293	Human KIR2DL2 / CD158b1 / NKAT-6 Protein, Fc Tag				Ajouter au panier

Quantité totale1

KIR2DL2Contexte de la molécule

Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.

KIR2DL2Alias de la molécule

CD158b1

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details